

## siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection

YONG CHEN<sup>1,2</sup> & RAM I. MAHATO<sup>2</sup>

<sup>1</sup>Huaian 4th People's Hospital, Jiangsu, People's Republic of China, and <sup>2</sup>Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38103-3308, USA

(Received 3 September 2007; accepted 5 January 2008)

### Abstract

The main objective was to determine whether a pool of small interfering RNAs (siRNAs) targeting different regions of hepatitis B virus surface antigen (HBsAg) efficiently inhibits hepatitis B virus (HBV) infection. siRNAs targeting different regions of HBsAg were transfected into HBV-producing HepG2.2.15 cells and at 72 h post-transfection, the culture medium was collected for ELISA to determine HBsAg, while total RNA was isolated from the cells for real-time PCR. Three siRNA sequences that efficiently inhibited HBV infection were converted into small hairpin RNAs (shRNAs) and then cloned into a single plasmid psiSTRIKE™ driven by a single U6 promoter. These shRNA expressing plasmids were tested for HBsAg gene silencing in HepG2.2.15 cells. A pool of siRNAs targeting HBsAg efficiently inhibited HBV replication and antigen expression when transfected into HepG2.2.15 cells, compared with the use of single siRNA. Similarly, the plasmid encoding three different shRNAs driven by a single U6 promoter was more effective in silencing HBsAg at DNA, mRNA and protein levels compared with the plasmid encoding single shRNA. No apoptotic change was observed in the cells when the plasmid was transfected at a dose of  $0.5-2 \mu\text{g}/1 \times 10^6$  cells after complex formation with Lipofectamine LTX™. Furthermore, transfection with siRNA or shRNA did not increase interferon- $\gamma$  (IFN- $\gamma$ ) release, suggesting no induction of IFN response. In conclusion, a pool of chemically synthesised siRNAs as well as the shRNA expression plasmid encoding multiple shRNAs targeting different regions of HBsAg showed high gene silencing in HepG2.2.15 cells.

**Keywords:** *Hepatitis B virus, siRNA, shRNA, HBV replication, HBsAg expression*

### Introduction

Infection with hepatitis B virus (HBV) is a global health problem, with over 350 million HBV carriers worldwide. Chronic infection by HBV may lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC; Wands and Blum 1991; Lau and Wright 1993; Lee 1997). Although, patients with chronic HBV infection have been treated with interferons (IFNs) and nucleoside analogues, available therapies are only partially effective against this viral infection. The low efficacy and undesirable side effects of IFNs and the occurrence of nucleoside analogues resistant HBV mutations remain major obstacles to anti-HBV therapy (Tipples et al. 1996;

Lai and Wu 1997; Dienstag et al. 2003). Liver injury induced by HBV infection is not due to virus replication or cytopathic effects on the infected cells, but due to the immune response against cells expressing viral antigens, especially hepatitis B virus surface antigen (HBsAg; Rapicetta et al. 2002). In addition, differences in the extent of HBV infection are determined by variations in the immune responses and expression of the HBV antigens in the liver tissue, which reflects the replicative status and the disease activity of chronic hepatitis B.

RNA interference (RNAi) is an evolutionarily conserved process by which double-stranded small interfering RNA (siRNA) induces sequence-specific,

Correspondence: R. I. Mahato, Department of Pharmaceutical Sciences, 19 S Manassas RM224, Memphis, TN 38103-3308, USA. Tel: 1 901 448 6929. Fax: 1 901 448 2099. E-mail: rmahato@utm.edu

post-transcriptional gene silencing of homologous genes in many eukaryotes (Fire et al. 1998; Montgomery and Fire 1998; Tabara et al. 1998; Couzin 2002; Plasterk 2002). RNAi usually involves processing of precursor double-stranded RNA (dsRNA) by DICER to form siRNA duplexes of 19–23 base pairs (Tijsterman and Plasterk 2004). The siRNA is then incorporated into the RNA-induced silencing complex, where one of the strands is selected and acts as a guide to target degradation of complementary cytoplasmic RNA.

RNAi has shown promise in inhibiting chronic HBV infection. Many researchers have demonstrated that specific and efficient siRNA can achieve silencing of HBV genes (Giladi et al. 2003; Konishi et al. 2003), which have prompted the development of RNA-based antiviral agents. As substrates for DICER, siRNA pool targeting different regions of a target genome has been shown to be more effective in gene silencing than a single siRNA duplex (De Paula et al. 2007). Therefore, the use of a single plasmid encoding multiple small hairpin RNA (shRNA) to target a range of sequences found in different target regions or viral genotypes will be of great interest. In the present study, we screened chemically synthesised siRNAs targeting different regions of HBsAg and then selected three potent siRNAs for converting into shRNAs to clone into a plasmid vector driven by a single U6 promoter. We then determined silencing efficiency of different shRNA expression plasmids at DNA, mRNA and protein levels. We demonstrate that plasmid encoding three different shRNAs against HBsAg is more effective than the plasmid encoding single shRNA, with little induction of IFN response.

## Materials and methods

### Materials

psiSTRIKE™ vector kit was purchased from Promega corporation (Madison, WI, USA). Antibiotic G418 was purchased from Sigma-Aldrich (St Louis, MO, USA). Bovine serum albumin (fraction V, purity > 98%) was purchased from USB corporation (Cleveland, OH, USA). Dulbecco's modified eagle's medium (DMEM), penicillin G (5000 Unit/ml), Trypsin-EDTA, Trizol, DNase I, Lipofectamine LTX™,

Lipofectamine2000, PureLink™ Viral RNA/DNA Mini Kit, monoclonal mouse anti-HBsAg and Alexa Fluor 488 goat anti-mouse IgG were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA). Restriction enzymes (*Pst*I, *Eco*RI, *Cla*I, *Bsr*GI, *Sgf*I and *Bgl*II) were purchased from New England Biolabs (Ipswich, MA, USA). SYBR Green-1 dye universal master mix and Multiscript reverse transcriptase were purchased from Applied Biosystems, Inc. (Foster, CA, USA). HBsAg ELISA kits were from Abazyme Company (Needham, MA, USA). siRNAs and primers were synthesised by Integrated DNA Technologies, Inc. (Coralville, IA, USA).

### siRNA design and synthesis

siRNAs targeting different regions of human HBsAg (Gene Bank Accession# NM\_U95551) were designed and their sequences are listed in Table I. These siRNAs are of 19–21 nt and 2-nt deoxynucleotide overhangs at the 3'-end and target-conserved S region of the ayw HBV genome. These siRNAs were designed according to the guide provided by Ambion ([http://www.ambion.com/techlib/misc/siRNA\\_finder.html](http://www.ambion.com/techlib/misc/siRNA_finder.html)) and Invitrogen (<https://rnaidesigner.invitrogen.com/rnaiexpress/design.do>). The sequence specificity of all siRNAs was checked by BLAST search ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)). All siRNAs were synthesised by Integrated DNA Technologies, Inc.

### Design and construction of shRNA expression plasmids

Following screening of different siRNA sequences, three effective sequences and control were chosen for converting into shRNAs against different target regions of HBsAg (Table IIA). To express shRNA of anti-HBsAg, pHBV-S1, pHBV-S2, pHBV-S4 and control vectors were constructed using psiSTRIKE™, which is a linearised plasmid and contains a U6 RNA polymerase promoter (Gou et al. 2003). These shRNAs contain two complementary oligonucleotides that were annealed to form double-stranded DNA for ligation into psiSTRIKE™ vector corresponding sites under U6 promoter using T4 DNA ligase for 2 h at 25°C. Following transformation in top 10 supercompetent cells and amplification in terrific broth media, plasmids were purified using

Table I. Sequences of siRNA and targeted sites of HBV.

siRNA	Target site	Sense sequence	Antisense sequence	Accession
siRNA-S1	256-274 nt	GUGGUGGACUUCUCUCAAUTT	AUUGAGAGAAGUCCACCACTT	U95551
siRNA-S2	322-342 nt	AACCUCCAAUCACUCACCAACTT	GUUGGUGAGUGAUUGGAGGUUTT	U95551
siRNA-S3	423-441 nt	GCCUCAUCUUCUUGUUGGUTT	ACCAACAAGAAGAUGAGGCTT	U95551
siRNA-S4	458-476 nt	GGUAUGUUGCCCGUUUGUCTT	GACAAACGGCAACAACCTT	U95551
Control-siRNA		GCAUAAUAAGUCAGUGCUUTT	AAGCACUGACUUAUUUGCTT	

Table II. Sequences of shRNA against different target regions of HBsAg.

shRNA	Sense sequence	Loop	Antisense sequence
A			
shRNA-S1: 256	5'-ACCGGTGGTGGACTTCTCTCAATCTTCTCTGTC AATTGAGAGAAGTCCACCACCTTTTTTC-3'		
shRNA-S2: 322	5'-ACCGGTGGTGGACTTCTCTCAATCTTCTCTGTC AATTGAGAGAAGTCCACCACCTTTTTTC-3'		
shRNA-S4: 458	5'-ACCGGTGGTGGACTTCTCTCAATCTTCTCTGTC AATTGAGAGAAGTCCACCACCTTTTTTC-3'		
Control-shRNA	5'-ACCGGCATAATAAGTCAGTGTCTTCTCTGTC AAAGCAGTCTGTTTGTATGGAAAAAGACGT-5'		
B			
shRNA-S1': 256	5'-AATTCGTGGTGGACTTCTCTCAATCTTCTCTGTC AATTGAGAGAAGTCCACCACAT-3'	EcoRI	<i>Cla</i> I
shRNA-S2': 322	5'-GTACAACCTCCAATCACTCACCAACCTTCTCTGTC AAGTGGTGGTGGAGGTTGCGAT-3'	<i>Bsr</i> GI	<i>Sgf</i> I
shRNA-S4': 458	5'-CGCGGTATGTTGCCCGTTTGTCTTCTCTGTC AAGCAGTCTGTTTGTATGGAAAAATCTAG-5'	<i>Sgf</i> I	<i>Bgl</i> II
Linker	5'-ACCGGAATTCGGATATCGATGTACAGCGGCCGCGATCGCGAC-3'		

QIAGEN<sup>®</sup> Plasmid Mini Kit (QIAGEN, Valencia, CA, USA). To construct pool shRNA expression plasmids pHBV-2S and pHBV-3S, a linker (sense strand: 5'-ACC GGA ATT CCG GAT ATC GAT GTA CAG CGG CCG CGA TCG CGA C-3, antisense strand: 5'-TGC AGT CGC GAT CGC GGC CGC TGT ACA TCG ATA TCC GGA ATT C-3') containing multiple restriction enzyme sites was synthesised and inserted into psiSTRIKE<sup>™</sup> plasmid, named as pEsiST vector. We used *Eco*RI and *Cla*I to digest pEsiST containing multiple restriction enzyme sites, and the sense (5'-AAT TCG TGG TGG ACT TCT CTC AAT CTT CCT GTC AAT TGA GAG AAG TCC ACC ACAT-3') and antisense (5'-CGAT GT GGT GGA CTT CTC TCA ATT GAC AGG AAG ATT GAG AGA AGT CCA CCA CG-3') strand of shRNA-S1' were annealed and cloned into *Eco*RI-*Cla*I sites of the pEsiST vector, named as pshRNA-S1' plasmid. We used *Sgf*I and *Bgl*II to digest pshRNA-S1' plasmid, and the sense (5'-CGC GGT ATG TTG CCC GTT TGT CCT TCC TGT CAG ACA AAC GGG CAA CAT ACC TTTT A-3') and antisense (5'-GATCT AAA AAG GTA TGT TGC CCG TTT GTC TGA CAG GAA GGA CAA ACG GGC AAC ATA CC GCGAT-3') strands of shRNA-S4' were annealed and cloned into *Sgf*I-*Bgl*II sites of the pshRNA-S1' plasmid, named as pHBV-2S plasmid, and the end of shRNA-S4' duplex contains a TTTTT stretch to create the pol III termination signal. Then we used *Bsr*GI and *Sgf*I to digest pHBV-2S plasmid, and the sense (5'-GTACA AAC CTC CAA TCA CTC ACC AAC CTT CCT GTC

AGT TGG TGA GTG ATT GGA GGT T GCGAT-3') and antisense (5'-CGC AAC CTC CAA TCA CTC ACC AAC TGA CAG GAA GGT TGG TGA GTG ATT GGA GGT TT-3') strands of shRNA-S2' were annealed and cloned into *Bsr*GI-*Sgf*I sites of the pHBV-2S plasmid, named as pHBV-3S vector plasmid. So two or three shRNA duplexes (Table IIB) were inserted into the psiSTRIKE<sup>™</sup> vector with a linker to create pHBV-2S and pHBV-3S vector plasmids (Figure 1).

#### Cell culture and transfection

HepG2.2.15 cell line was kindly provided by Dr Pamela Norton of the Department of Microbiology and Immunology, Drexel University College of Medicine. HepG2.2.15 cell line was cultured in DMEM supplemented with 4% fetal bovine serum and 330 µg/ml antibiotic G418 at 37°C in a humidified incubator with 5% CO<sub>2</sub>. Twenty four hours before transfection, cells were trypsinised and seeded in 24-well culture plates at a density of 1 × 10<sup>5</sup> cells per well. The cells were transfected with 40 and 80 nmol/l siRNAs after complex formation with Lipofectamine2000 at 1 µg/1 µg ratio. In case of shRNA expression plasmids, cells were transfected with shRNA expression vectors at doses of 0.5, 1, 2 µg/well after complex formation with Lipofectamine LTX<sup>™</sup> according to the manufacturer's protocol. At 72 h post-transfection, the cells were harvested and culture supernatant was collected for further analysis.




Figure 1. Construction of a shRNA expression vector encoding multiple siRNAs driven by a single U6 promoter. Three oligonucleotides containing a hairpin sequence, terminator sequence, and overhanging sequence as restriction sites were annealed and cloned into a psiSTRIKE™ vector.

#### Measurement of particle size and $\zeta$ potential

Plasmid (0.5, 1 and 2  $\mu\text{g}$ ) and Lipofectamine LTX™ (1, 2 and 4  $\mu\text{l}$ ) were diluted separately to a volume of 250  $\mu\text{l}$  with a final glucose concentration of 5% w/v, and then the DNA was added to the Lipofectamine LTX™ with mild mixing by pipetting. Complex formation was allowed to proceed for 45 min at room temperature. Lipid/plasmid complexes of different charge ratios were prepared by adjusting the stoichiometry of plasmid and Lipofectamine LTX™. The particle size and  $\zeta$  potential of Lipofectamine LTX™/plasmid complexes were determined by dynamic light scattering at 25°C using a Malvern Zetasizer (Southborough, MA, USA) as described by Wang et al. (2002).

#### Quantification of HBsAg mRNA and culture medium HBV DNA by real-time PCR

HBV virion DNA in culture medium and intracellular HBsAg mRNA levels were determined by real time PCR and real time RT-PCR, respectively, after transfection of HepG2.2.15 cells with siRNA or shRNA expression plasmids. Following transfection, the culture medium was collected and total RNA was extracted from the cell pellet with Trizol, and RNA concentration was measured by UV spectrophotometry using Biomate three spectrophotometer (ThermoSpectrom, Waltham, MA, USA). Then,

200 ng of DNase I-treated total RNA was reverse-transcribed to cDNA by Multiscript reverse transcriptase in a 10  $\mu\text{l}$  reaction system containing oligo (dT) final concentration 2.5  $\mu\text{M}$  for 10 min at 25°C, 30 min at 48°C and 5 min at 95°C. Reverse-transcribed cDNA was quantified by real-time PCR using SYBR Green-1 dye universal master mix and HBV primers specific for the S gene: sense strand: 5'-GAT TCC TAG GAC CCC TTC TC-3', antisense strand: 5'-GGA GGA CAG GAG GTT GGT GA-3'. Because of its invariant expression across tissues and treatments, 18S ribosomal RNA was used as an internal control for quantitative RNA analysis: forward: 5'-CGG CTA CCA CAT CCA AGG AA-3', reverse: 5'-GCT GGA ATT ACC GCG GCT-3'. Amplification and detection were performed with an ABI 7700 sequence detection system. The real-time PCR conditions were as follows: 50°C, 2 min; 95°C, 10 min; 95°C, 15 s; 54°C, 1 min,  $\times$  40 cycles; 72°C, 5 min. Three independent experiments were performed and the amount of reverse transcribed cDNA in treated cultures was expressed as a percentage of the mock-treated controls. Results were analysed with SDS 2.0 software from Applied Biosystems.

HBV DNA was extracted from 200  $\mu\text{l}$  culture medium using a PureLink™ Viral RNA/DNA Mini Kit (Carlsbad, CA, USA). Purified HBV DNA was quantified by real-time PCR using the primers and conditions described above.




Figure 2. Inhibition of HBsAg expression after transfection of chemically synthesised siRNAs into HepG2.2.15 cells upon complex formation with Lipofectamine2000. (A) mRNA level and (B) protein level. The amount at HBsAg mRNA and HBsAg protein levels were determined by real time RT-PCR and ELISA, respectively, at 72 h post-transfection.

### Immunofluorescence and confocal microscopy

At 72 h after transfection of HepG2.2.15 cells with shRNA expression plasmids, the cells were fixed with 3% paraformaldehyde for 15 min, washed three times with Dulbecco's phosphate buffered saline (DPBS), permeabilised with 0.1% Brij98/PBS for 2 min, washed two times with DPBS and blocked with 20% goat serum for 30 min. Cells were sequentially incubated with monoclonal mouse anti-HBsAg primary antibody and Cy3-goat anti-mouse IgG conjugated secondary antibody at room temperature for 1 h, and mounted on the fixed cell slip. The cells were observed with Bio-Rad 1024 confocal microscope (Bio-Rad, Hercules, CA, USA) at 488 nm excitation wavelength.

## Results

### Effect of siRNA sequences on gene silencing

To examine the ability of siRNA to silence HBV gene expression, we selected HBsAg as a target gene. We compared four different 19–21 bp siRNA duplexes targeted to different regions of the HBsAg open reading frame along the HBV genome (Table I). These siRNA duplexes were transfected into HepG2.2.15 cells either alone or as a pool of all four siRNAs after complex formation with Lipofectamine2000. As shown in Figure 2, HBsAg gene silencing by siRNAs was sequence specific and dose dependent. Three siRNAs had caused a significant decrease in HBsAg mRNA levels, while the control siRNA had almost no effect on HBsAg gene expression. The level of HBsAg mRNA was reduced by 40.9, 13.41, 17.4 and 40.16% for siRNA-S1, siRNA-S2, siRNA-S3 and siRNA-S4 treated samples, respectively, when transfected at the dose of 40 nmol/l. There was significant increase in HBsAg gene silencing as we increased the siRNA dose to 80 nmol/l, being 71.77, 58.79, 54.49 and 84.69% for

siRNA-S1, siRNA-S2, siRNA-S3 and siRNA-S4, treated samples, respectively (Figure 2(A)).

We also determined the level of HBsAg secreted into the culture medium at 3 days post-transfection by ELISA. The levels of HBsAg into the medium were reduced by 39.67, 31.79, 30.55 and 42.29% for siRNA-S1, siRNA-S2, siRNA-S3 and siRNA-S4 treated samples, respectively, when transfected at the dose of 40 nmol/l. There was significant increase in HBsAg gene silencing, leading to significant decrease in HBsAg concentration in the culture medium as we increased siRNA dose to 80 nmol/l: 58.72, 55.03, 46.01 and 61.71% for siRNA-S1, siRNA-S2, siRNA-S3 and siRNA-S4 treated samples, respectively (Figure 2(B)). Among these four siRNA duplexes, siRNA-S4 showed the highest gene silencing ability at both mRNA and protein levels: 84.69 and 61.71% inhibition of HBsAg at mRNA and protein levels when HepG2.2.15 cells were transfected at the dose of 80 nmol/l. Other siRNAs resulted in varying degrees of inhibition for HBsAg expression. The control siRNA had no effect on HBsAg levels in the media of the treated cells, indicating that inhibition by the HBsAg targeted siRNAs was sequence specific and due to RNAi. Combination of four siRNAs was more effective in the inhibition of HBsAg mRNA and antigen expression as compared with the use of any one while the final concentration of siRNAs in those treatments was the same.

### Construction of shRNA expression vectors

Following screening of different siRNA sequences for HBsAg gene silencing, we selected the three most potent siRNA sequences for converting into shRNA sequences, which contain unique restriction sites at the 5' and 3' ends for cloning and a TTTT stretch in the sense to create the pol III terminal signal (Table II). Then, these shRNA sequences were cloned into psiSTRIKE™ as illustrated in Figure 1. pHBV-S1,




Figure 3. Transfection of shRNA expression plasmids into HepG2.2.15 cells. The effect of pHBV-S1, pHBV-S2, pHBV-S4, pHBV-2S and pHBV-3S plasmids on HBsAg gene silencing was determined at (A) protein, (B) RNA and (C) DNA levels by ELISA, real time RT-PCR and real time PCR, respectively, at 72 h post-transfection.

pHBV-S2 and pHBV-S4 were identified using restriction enzyme digestion assay which yielded two DNA fragments of about 3047 and 1370 bp (results not shown). The pHBV-2S and pHBV-3S vectors were identified by digestion with *Eco*RI and *Bgl*II enzymes. The length of products of pHBV-2S and pHBV-3S were 118 and 163 bp, respectively (results not shown). The DNA sequencing result showed the inserted fragment had expected known sequences.

#### Effect of shRNA expression on HBsAg secretion

To evaluate the influence of siRNA pool on HBV life cycle, we used psiSTRIKE™ vector to direct the synthesis of multiple siRNAs in HepG2.2.15 cell line. Following cloning, amplification and purification of pHBV-S1, pHBV-S2, pHBV-S4, pHBV-2S and pHBV-3S, we formed lipid/plasmid complexes by mixing equal volumes of Lipofectamine and shRNA expression plasmid, and determined the particle size and  $\zeta$  potential by a dynamic light scattering technique. These lipid/plasmid complexes had mean particle size of 200–400 nm and  $\zeta$  potential of 20–30 mV. We then determined the effect of shRNA expression plasmids on HBsAg gene silencing after transfection of Lipofectamine/pHBV complexes into HepG2.2.15 cells at doses of 0.5, 1 and 2 µg/well. Variable efficacy of HBsAg gene silencing was achieved by each of the sequences (Figure 3). Compared with the control shRNA plasmid transfected group, transfection of HepG2.2.15 cells with the plasmids

encoding shRNAs against HBsAg significantly inhibited HBsAg concentrations in the culture medium (Figure 3(A)). The plasmid encoding three shRNAs (pHBV-3S) decreased HBsAg concentration in the culture supernatant to less than 15% of the control shRNA-treated cell level. Compared with the plasmids encoding single shRNA, the plasmids encoding three shRNAs targeting different regions of HBsAg genome were more effective in HBsAg gene silencing.

We also extracted total cellular RNA from transfected HepG2.2.15 cells and subjected to real time RT-PCR. The results confirmed that the plasmid encoding three shRNAs (pHBV-3S) efficiently reduced HBsAg mRNA concentration by 63.2–87.7% of the control at different concentrations of plasmid when normalised using 18S RNA (Figure 3(B)).

We also determined HBV virion DNA after extraction from the culture medium by real time PCR. As shown in Figure 3(C), the levels of HBV virion DNA significantly decreased when HepG2.2.15 cells were transfected with the plasmid encoding shRNA against HBsAg. There was almost 85% inhibition when the plasmid encoding three shRNAs (pHBV-3S) was used for transfection.

#### Confocal immunofluorescent analysis of HBsAg expression

To further substantiate our observations, HepG2.2.15 cells were transfected with shRNA expression plasmids. At 72 h after transfection, cells were




Figure 4. RNAi effects of plasmid encoding shRNA against HBsAg in HepG2.2.15 cells. The cells were seeded on cover slips in 24-well plates and transfected with 1  $\mu$ g/well of shRNA expression plasmids. At 72 h post-transfection, cells were fixed, immunostained for HBsAg protein and visualised under a confocal microscope. These results show that HBsAg expression levels reduced to a different extent in treated cells compared with the control plasmid-treated samples.

immunostained for HBsAg and analysed by confocal microscopy. The photographs shown in Figure 4 suggest that the intensity of HBsAg staining was the strongest for non-transfected HepG2.2.15 cells, which releases hepatitis B viral particles. Following transfection with shRNA against HBsAg, there was decrease in the intensity of HBsAg staining in the following order: HBV-S1 > HBV-S2 > HBV-S4 > HBV-2S > HBV-3S. The results suggest that HBsAg levels in cells transfected with shRNA plasmids were reduced to different extent compared with the control plasmid. The cells transfected with pHBV-2S and pHBV-3S plasmids showed little fluorescence, suggesting little HBsAg expression.

#### *IFN response of shRNA induction*

To determine whether shRNA induces IFN response pathway, at 72 h post-transfection of HepG2.2.15 cells with shRNA expression plasmids, IFN- $\gamma$  release in the culture supernatants was determined by ELISA. Transfection with shRNA expression plasmids did not increase IFN- $\gamma$  concentration and IFN- $\gamma$  levels for all the samples were between 5–6 pg/ml, suggesting no induction of IFN response (data not shown).

#### **Discussion**

RNAi is a sequence-specific, post-transcriptional gene silencing mechanism, which is triggered by double-stranded synthetic siRNA or shRNA expressed intracellularly from a vector (Brummelkamp et al. 2002; Miyagishi and Taira 2002). Recently, several groups have reported that HBV replication and expression could be inhibited in human hepatoma cell culture and mouse models after direct application of either synthetic siRNAs or endogenously expressed shRNAs (Giladi et al. 2003; McCaffrey et al. 2003; Shlomai and Shaul 2003). HBV gene silencing was dependent primarily on siRNA dose and sequences.

The humoral (antibody) response to epitopes on HBsAg that envelops the virus is responsible for protective immunity against HBV infection and clearance of HBV from the body (Lok et al. 1985; Milich et al. 1987; Barnaba et al. 1990). As HBsAg-specific immunity response is poor, it is widely accepted that the HBsAg-specific immunity response supports anti-HBsAg production (Milich et al. 1987). Chronic HBV infection is associated with HBsAg expression, and almost all the HBV-associated HCC

harbored chromosomally integrated viral DNA (Chu et al. 1985; Chu and Liaw 1997). Although, HBxAg has been implicated in the process of HCC, the viral DNA-integrated genome is commonly found with partial or complete deletion of HBx gene (Yen and Hepadnaviral 1996; Chen et al. 2000). Moreover, the development of HCC is preceded by chronic liver injury and inflammation. Studies on HBsAg transgenic mice revealed that a severe, prolonged hepatocellular injury, regenerative hyperplasia and a secondary inflammation preceded HCC (Dunsford et al. 1990; Toshkov et al. 1994; Nakamoto et al. 1998). Therefore, strategies for treating chronic HBV infection should not be restricted to inhibition of virus replication, and suppression of HBsAg expression should also be considered.

The design of effective siRNAs has been a major obstacle in siRNA-mediated gene silencing, as there is great variability among siRNAs, in terms of their effectiveness. There are often more than one target regions of a given gene, which can be efficacious in gene silencing. To determine whether we can use RNAi technology to treat HBV-induced diseases caused by aberrant or persistent expression of HBsAg, we screened four chemically synthesised siRNA duplexes targeting 256, 322, 423 and 458 nt start sites of HBsAg (Table I). As shown in Figure 2, these siRNA duplexes could significantly inhibit HBsAg synthesis to different extents after transfection into HepG2.2.15 cells. Among the four siRNAs we had tested, siRNA-S4 was found to be the most potent in inhibiting HBsAg expression *in vitro*. Compared with a single siRNA duplex, the highest level of HBsAg gene silencing was achieved when we used a pool of three siRNA duplexes targeting a different region of HBsAg (Figure 2). The rest three siRNAs also inhibited HBsAg to a different extent (McCaffrey et al. 2003; Cheng et al. 2005). The difference in inhibition among various siRNA may be attributed to the change of affinity between cellular siRNA binding protein and the secondary and/or tertiary structures of target mRNA participating in the induction of RNAi activities (Hammond et al. 2001).

Since, we achieved high levels of HBsAg gene silencing when we using a pool of chemically synthesised siRNAs, we postulated that multiple shRNAs cloned into a single U6 promoter would produce a pool of siRNAs after cleavage of dsRNA by DICER, leading to significant increase in the intracellular siRNA levels. To prove this hypothesis, we constructed plasmid vectors encoding a pool of two or three shRNAs driven by a single U6 promoter. As shown in Figures 3 and 4, very high levels of HBsAg gene silencing were achieved when using these plasmids, as confirmed by ELISA, real time PCR and immunofluorescence assays (Figures 3 and 4). mRNA molecules in cells may also have a repairing mechanism like DNA while it is cleaved by biological,

chemical or physical forces. shRNA pool can cleave multiple sites in mRNA target region and may achieve greater gene silencing than a single shRNA. Similar results were also reported in the literature using large dsRNA and long shRNA (Cheng et al. 2005; Peng et al. 2005). While we and these authors achieved high gene silencing compared with single shRNA, our strategy is somewhat different from theirs. The long shRNA comprises 62 bp with multiple G:U wobble pairings to facilitate cleavage into multiple siRNAs by DICER (Weinberg et al. 2007). With large dsRNA, formation of siRNAs is likely to proceed with decreased precision and may contribute to off-target effects, since large dsRNA usually traverses the endosomal compartments and interacts with Toll-like receptors. In contrast, we cloned multiple shRNAs together by keeping poly(T) at the end (Figure 1). Moreover, our expressed shRNA is unlikely to have the same immunostimulatory properties as synthetic siRNA, since shRNA transcribed within cells does not typically traverse the endosomal compartments.

In the present study, we studied the silencing effect of siRNA pool targeting three different sites of HBV S gene region, but silencing of other gene regions (C, P, X) of HBV genome at the same time has a great potential for inhibiting HBV infection. This was confirmed in a study that showed that transfecting cells with a panel of siRNAs produced *ex vivo* using recombinant DICER is a useful means of attaining reliable silencing (Myers and Ferrell 2005). Our strategy to produce several siRNAs from a single plasmid encoding multiple shRNAs (Figure 1) is somewhat similar to long shRNA (lshRNAs; Weinberg et al. 2007) and should improve the probability of assembling effective silencing complexes.

Chemically synthesised siRNA duplex may induce unintended programmed cell death due to stimulation of several inflammatory cytokines and nonspecific gene silencing. Therefore, we measured the relative levels of IFN- $\gamma$  in HepG2.2.15 cells that were transfected with plasmids encoding shRNAs against HBsAg. We did not find any induction of IFN response, as the IFN- $\gamma$  levels for all the samples were between 5 and 6 pg/ml (data not shown). This is in the good agreement with the literature, where expressed hairpins have been shown to evade activation of the IFN response more efficiently than exogenous synthetic RNA (Robbins et al. 2006). Weinberg et al. (2007) also reported no evidence of IFN response induction when transfected Huh7 cells with long hairpin RNA target HBx together with HBV target plasmid.

It is important to use a combination of several effective shRNAs against HBV S, C, P X genes to achieve a complete inhibition of HBV replication and gene expression. Further, investigation is warranted to advance towards this goal.

## Acknowledgements

We thank the National Institutes of Health for financial support (R01 DK069968 and R01 DK064633), USPH Grant 47379. Yong Chen was a recipient of the funding (H200118) from the Department of Public Health of Jiangsu Province, China.

## References

- Barnaba V, Franco A, Alberti A, Benvenuto R, Balsano F. 1990. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. *Nature* 345(6272):258–260.
- Brummelkamp TR, Bernards R, Agami R. 2002. A system for stable expression of short interfering RNAs in mammalian cells. *Science* 296(5567):550–553.
- Chen WN, Oon CJ, Leong AL, Koh S, Teng SW. 2000. Expression of integrated hepatitis B virus X variants in human hepatocellular carcinomas and its significance. *Biochem Biophys Res Commun* 276(3):885–892.
- Cheng TL, Chang WW, Su IJ, Lai MD, Huang W, Lei HY, Chang WT. 2005. Therapeutic inhibition of hepatitis B virus surface antigen expression by RNA interference. *Biochem Biophys Res Commun* 336(3):820–830.
- Chu CM, Karayiannis P, Fowler MJ, Monjardino J, Liaw YF, Thomas HC. 1985. Natural history of chronic hepatitis B virus infection in Taiwan: Studies of hepatitis B virus DNA in serum. *Hepatology* 5(3):431–434.
- Chu CM, Liaw YF. 1997. Natural history of chronic hepatitis B virus infection: An immunopathological study. *J Gastroenterol Hepatol* 12(9–10):S218–S222.
- Couzin J. 2002. Breakthrough of the year. Small RNAs make big splash. *Science* 298(5602):2296–2297.
- De Paula D, Bentley MV, Mahato RI. 2007. Effect of iNOS and NF- $\kappa$ B gene silencing on beta-cell survival and function. *J Drug Target* 15(5):358–369.
- Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E. 2003. Durability of serologic response after lamivudine treatment of chronic hepatitis B. *Hepatology* 37(4):748–755.
- Dunsford HA, Sell S, Chisari FV. 1990. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. *Cancer Res* 50(11):3400–3407.
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in *C. elegans*. *Nature* 391(6669):806–811.
- Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. 2003. Small interfering RNA inhibits hepatitis B virus replication in mice. *Mol Ther* 8(5):769–776.
- Gou D, Jin N, Liu L. 2003. Gene silencing in mammalian cells by PCR-based short hairpin RNA. *FEBS Lett* 548(1–3):113–118.
- Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. 2001. Argonaute2, a link between genetic and biochemical analyses of RNAi. *Science* 293(5532):1146–1150.
- Konishi M, Wu CH, Wu GY. 2003. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. *Hepatology* 38(4):842–850.
- Lai CL, Wu PC. 1997. Antiviral treatment for chronic hepatitis B. *Hong Kong Med J* 3(3):289–296.
- Lau JY, Wright TL. 1993. Molecular virology and pathogenesis of hepatitis B. *Lancet* 342(8883):1335–1340.
- Lee WM. 1997. Hepatitis B virus infection. *N Engl J Med* 337(24):1733–1745.
- Lok AS, Karayiannis P, Jowett TP, Fowler MJ, Farci P, Monjardino J, Thomas HC. 1985. Studies of HBV replication during acute hepatitis followed by recovery and acute hepatitis progressing to chronic disease. *J Hepatol* 1(6):671–679.
- McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA. 2003. Inhibition of hepatitis B virus in mice by RNA interference. *Nat Biotechnol* 21(6):639–644.
- Milich DR, McLachlan A, Thornton GB, Hughes JL. 1987. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. *Nature* 329(6139):547–549.
- Miyagishi M, Taira K. 2002. U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. *Nat Biotechnol* 20(5):497–500.
- Montgomery MK, Fire A. 1998. Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. *Trends Genet* 14(7):255–258.
- Myers JW, Ferrell JE. 2005. Silencing gene expression with dicer-generated siRNA pools. *Methods Mol Biol* 309:93–196.
- Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. 1998. Immune pathogenesis of hepatocellular carcinoma. *J Exp Med* 188(2):341–350.
- Peng J, Zhao Y, Mai J, Pang WK, Wei X, Zhang P, Xu Y. 2005. Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties. *J Gen Virol* 86(Pt 12):3227–3234.
- Plasterk RH. 2002. RNA silencing: The genome's immune system. *Science* 296(5571):1263–1265.
- Rapicetta M, Ferrari C, Levrero M. 2002. Viral determinants and host immune responses in the pathogenesis of HBV infection. *J Med Virol* 67(3):454–457.
- Robbins MA, Li M, Leung I, Li H, Boyer DV, Song Y, Behlke MA, Rossi JJ. 2006. Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs *in vitro*. *Nat Biotechnol* 24(5):566–571.
- Shlomai A, Shaul Y. 2003. Inhibition of hepatitis B virus expression and replication by RNA interference. *Hepatology* 37(4):764–770.
- Tabara H, Grishok A, Mello CC. 1998. RNAi in *C. elegans*: Soaking in the genome sequence. *Science* 282(5388):430–431.
- Tijsterman M, Plasterk RH. 2004. Dicers at RISC; the mechanism of RNAi. *Cell* 117(1):1–3.
- Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine *in vivo*. *Hepatology* 24(3):714–717.
- Toshkov I, Chisari FV, Bannasch P. 1994. Hepatic preneoplasia in hepatitis B virus transgenic mice. *Hepatology* 20(5):1162–1172.
- Wands JR, Blum HE. 1991. Primary hepatocellular carcinoma. *N Engl J Med* 325(10):729–731.
- Wang DA, Narang AS, Kotb M, Gaber AO, Miller DD, Kim SW, Mahato RI. 2002. Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. *Biomacromolecules* 3(6):1197–1207.
- Weinberg MS, Ely A, Barichiev S, Crowther C, Mufamadi S, Carmona S, Arbuthnot P. 2007. Specific inhibition of HBV replication *in vitro* and *in vivo* with expressed long hairpin RNA. *Mol Ther* 15(3):534–541.
- Yen TS. 1996. Hepadnaviral X protein: Review of recent progress. *J Biomed Sci* 3(1):20–30.